Gattex (teduglutide) is dosed at 0.05 mg/kg once daily by subcutaneous injection in adults with short bowel syndrome (SBS), making it a weight-based regimen that varies from patient to patient. Pediatric dosing follows a similar weight-based approach but includes a lower starting option. Because the drug is cleared through the kidneys, people with significant kidney impairment need a reduced dose. The specifics of how to calculate, prepare, and adjust Gattex dosing are more involved than a single number, and they matter because getting the dose right directly affects how much parenteral nutrition a patient can eventually reduce or eliminate.
How Gattex Works and Why the Dose Matters
Gattex is a lab-made version of a naturally occurring gut hormone called glucagon-like peptide 2 (GLP-2). In a healthy digestive system, GLP-2 helps maintain the lining of the intestine. Teduglutide mimics that hormone but lasts longer in the body, promoting the growth of intestinal tissue and improving its ability to absorb nutrients and fluids. In clinical trials, treatment was associated with significant reductions in diarrhea and equivalent reductions in the need for parenteral support (IV nutrition) in patients with SBS and intestinal failure.1PubMed Central. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome
At the cellular level, teduglutide does more than just make the intestinal lining thicker. Research in animal models of SBS shows it also changes how the cells lining the gut handle sodium and water. It enhances the function of tight junctions between cells and redistributes a protein called claudin-10, which helps recirculate sodium in a way that supports glucose transport and water absorption.2PubMed Central. Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency This dual action, growing more tissue and making existing tissue work better, is why consistent daily dosing is important. The intestinal changes build over weeks and months, so missing doses or using an incorrect amount undermines the slow rehabilitation of the gut.
Standard Adult Dose
For adults, the recommended dose is 0.05 mg/kg given as a single subcutaneous injection once per day. In a pivotal 24-week clinical trial, this dose produced significant reductions in the volume of parenteral support patients needed compared with placebo.3PubMed. Teduglutide: a guide to its use in short bowel syndrome Real-world use has followed the same protocol. In a study of patients with Crohn’s disease who had SBS-associated intestinal failure, all patients were started on the recommended 0.05 mg/kg/day dose.4PubMed Central. Safety and Efficacy of Teduglutide in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome associated intestinal failure
In practical terms, a person weighing about 70 kg (roughly 154 pounds) would receive around 3.5 mg per injection. The drug comes as a powder that needs to be mixed with a supplied diluent right before injection. You inject it into the abdomen, thigh, or upper arm, rotating sites to avoid irritating the same spot repeatedly. The injection itself is straightforward, and most patients or caregivers learn to do it at home after initial training.
Pediatric Dosing
Children with SBS have been studied at two dose levels: 0.025 mg/kg/day and 0.05 mg/kg/day. In a 24-week phase III trial, both dose groups showed clinically significant reductions in parenteral support volume compared with standard of care alone. At the higher dose, about 69% of patients achieved at least a 20% reduction in parenteral support, compared with roughly 54% at the lower dose and only 11% in the standard-of-care group.5Journal of Parenteral and Enteral Nutrition. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study A small number of children in each teduglutide group achieved full enteral autonomy, meaning they no longer needed IV nutrition at all.
Beyond parenteral support reductions, pediatric patients treated with teduglutide also showed improved stool consistency and increased enteral nutrition volume. By week 24, stool scores on a standard consistency scale improved significantly, and children were tolerating more nutrition by mouth or feeding tube.6Journal of Pediatric Gastroenterology and Nutrition. Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome‐Associated Intestinal Failure The choice between the lower and higher pediatric dose is typically made by the prescribing physician based on the child’s clinical status and tolerance.
Dose Adjustments for Kidney Impairment
Teduglutide is cleared from the body primarily through the kidneys, and its pharmacokinetics change meaningfully when kidney function declines. In a dedicated study, people with end-stage renal disease had drug exposure (measured by the area under the concentration-time curve) roughly 2.6 times higher than healthy subjects, and peak blood levels about twice as high. Even moderate and severe kidney impairment produced somewhat elevated levels.7PubMed. Pharmacokinetics of teduglutide in subjects with renal impairment Because of this, the prescribing information calls for a 50% dose reduction in patients with moderate-to-severe renal impairment (creatinine clearance below 50 mL/min) and in those on dialysis, bringing the adult dose down to 0.025 mg/kg/day.
Population pharmacokinetic modeling has confirmed that both body weight and kidney function are the main factors influencing how much drug a patient is exposed to after a standard dose. Body weight also drives the volume of distribution and, in children, age plays an additional role. Despite these differences, peak drug concentrations ended up being similar across adult and pediatric patients, and across Japanese and non-Japanese populations, suggesting the weight-based dosing approach works reasonably well across diverse groups.8PubMed Central. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome
How Long Treatment Lasts
Gattex is not a short-course therapy. The drug’s half-life in the bloodstream is only about an hour and a half, which is why daily injections are necessary.9PubMed Central. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome But the intestinal changes it produces build gradually. The pivotal trials ran for 24 weeks, and many patients continue treatment well beyond that. In the Crohn’s disease-specific cohort, the median treatment duration was about a year, with the majority of patients still on therapy at the end of follow-up.10PubMed Central. Safety and Efficacy of Teduglutide in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome associated intestinal failure
What happens if you stop? The intestinal gains achieved during treatment do not appear to be permanent. Most clinicians expect some reversal of the mucosal growth when the drug is discontinued, which is why patients who are responding well typically stay on Gattex indefinitely unless a compelling reason arises to stop. There is no established tapering protocol; the decision to continue, pause, or discontinue is based on clinical judgment and how much parenteral support the patient still requires.
Weaning Parenteral Nutrition While on Gattex
The whole point of Gattex dosing is to reduce, and ideally eliminate, a patient’s dependence on IV nutrition. But reducing parenteral support is not as simple as starting the drug and cutting back on a fixed schedule. Weaning should be individualized, taking into account fluid and electrolyte balance, urine output, weight trends, and the patient’s overall nutritional status.11PubMed. Weaning from Parenteral Nutrition Most clinicians reduce parenteral support in small increments, every few weeks, while carefully monitoring for signs of dehydration or malnutrition.
As Gattex improves intestinal absorption, it can also change how medications taken by mouth are absorbed. A drug that was poorly absorbed before treatment might suddenly reach higher blood levels as the gut rehabilitates. This is especially relevant for narrow therapeutic index medications like warfarin, certain anti-seizure drugs, or thyroid hormone replacement. Clinicians managing Gattex patients need to stay alert to these shifts and recheck drug levels or clinical responses as parenteral support volumes come down.
Tracking Response With Citrulline
One practical question during treatment is whether the drug is actually working, especially before parenteral support reductions become obvious. Plasma citrulline, an amino acid produced mainly by intestinal cells, serves as a rough biomarker for how much functional intestinal tissue a patient has. In two phase III trials, patients on teduglutide at the standard 0.05 mg/kg/day dose saw citrulline levels rise by about 67% to 111% over 24 weeks, compared with only 8% to 13% in placebo groups. These increases started early, often visible by week four, and climbed most steeply in the first eight weeks.12PubMed Central. Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials
In pediatric patients, citrulline also rises with treatment, though the magnitude of change varies depending on which part of the intestine remains. Children with different remnant bowel anatomies showed different citrulline trajectories, suggesting that the biomarker response is not one-size-fits-all.13Children. Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine A rising citrulline level does not by itself prove a patient can tolerate less IV nutrition, but a flat citrulline after several weeks might prompt the care team to reassess whether the treatment is having its intended effect.
Safety Monitoring and Screening
Because Gattex promotes tissue growth in the gut, prescribers are required to screen for colorectal polyps before starting therapy and to perform surveillance colonoscopies during treatment. Patients with active gastrointestinal malignancy should not receive the drug. Gallbladder and biliary tract complications, including cholecystitis and cholelithiasis, have been reported, so monitoring for biliary symptoms is part of routine care. Pancreatitis, fluid overload (especially as IV fluids are being weaned), and intestinal obstruction are other risks that clinicians watch for.
The management of patients on teduglutide is complex and requires close monitoring across multiple dimensions: efficacy, safety, nutritional adequacy, and fluid balance.14Nutrition in Clinical Practice. Use of teduglutide in adults with short bowel syndrome–associated intestinal failure Most patients are managed at specialized intestinal rehabilitation centers where multidisciplinary teams, including gastroenterologists, surgeons, dietitians, and pharmacists, coordinate care. This is not a drug where a general practitioner writes a prescription and checks in at the next annual physical.
The Cost Problem
Gattex is one of the most expensive chronic medications on the market, with annual costs running into six figures for many patients. A study examining real-life healthcare costs in children with SBS found that when the price of teduglutide was added to the analysis, total costs increased significantly in the treated group. Even after modeling a hypothetical reduction in drug cost to one-third of its current price, combined with savings from parenteral nutrition weaning, the total cost in treated patients remained substantially higher.15PubMed. The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome
This creates a difficult situation. Parenteral nutrition itself is expensive, carries long-term risks like liver disease and bloodstream infections from central venous catheters, and dramatically affects quality of life. Gattex can reduce or eliminate those burdens, and patients in clinical trials reported quality-of-life improvements alongside their parenteral support reductions.16PubMed. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide–analyses from a randomised, placebo-controlled study But the drug’s price tag means access often depends on insurance coverage decisions, and some families and patients face protracted battles with payers to maintain treatment even when it is clearly working.
What May Change With Newer GLP-2 Drugs
The daily injection schedule is one of the practical burdens of Gattex. Several next-generation GLP-2 analogs in development aim to extend the dosing interval. Glepaglutide, for example, is a long-acting GLP-2 analog formulated in a stable liquid solution that does not need reconstitution. Pharmacokinetic studies in healthy subjects showed that glepaglutide has a significantly longer duration of action than teduglutide, supporting the possibility of once- or twice-weekly dosing instead of daily injections.17PubMed Central. Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
For patients who are self-injecting daily and reconstituting a powder before each shot, switching to a ready-to-use liquid given once a week would be a meaningful quality-of-life improvement. Competition in this space could also eventually put downward pressure on pricing. Apraglutide is another long-acting analog in late-stage clinical trials with a similar weekly dosing ambition. If these drugs reach the market, the landscape of GLP-2 therapy for SBS could look substantially different within the next several years, with daily dosing potentially becoming a thing of the past for newly diagnosed patients.
Patients With Crohn’s Disease
A significant portion of SBS patients develop their condition as a result of multiple intestinal surgeries for Crohn’s disease. This raises a unique concern: could a drug that promotes intestinal growth cause problems in a disease characterized by abnormal immune activity in the gut? The available evidence, though limited, has been reassuring. In a study tracking 13 Crohn’s patients on teduglutide, about 62% were also on immunosuppressive therapy. The majority remained on Gattex at the conclusion of follow-up, with no reported exacerbations attributed to the drug.18PubMed Central. Safety and Efficacy of Teduglutide in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome associated intestinal failure The sample sizes here are small, though, and clinicians tend to be cautious about starting Gattex in patients with active Crohn’s inflammation rather than stable, surgically induced short bowel.
The interplay between immunosuppression and a growth-promoting gut hormone is an area where clinical judgment runs ahead of robust data. Most practitioners feel comfortable using Gattex in Crohn’s patients who are in remission and on stable immunosuppressive regimens, but there is no large randomized trial that definitively settles the question of whether teduglutide might influence disease recurrence over many years of use.